Evidence map›Paper›PMID 40095204›Full record

ReviewThe Australasian journal of dermatology2025

Targeted Therapies for Slow-Flow Vascular Malformations.

Grace X Li, Deshan F Sebaratnam, James P Pham

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Australasian journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Grace X LiFaculty of Medicine and Health, University of New South Wales, Kensington, New South Wales, Australia.ORCID https://orcid.org/0009-0007-3201-9573
Deshan F SebaratnamFaculty of Medicine and Health, University of New South Wales, Kensington, New South Wales, Australia.
James P PhamFaculty of Medicine and Health, University of New South Wales, Kensington, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in genetic sequencing technologies have enabled the identification of key activating somatic variants in cellular signalling pathways involved in the pathogenesis of vascular malformations. Given that these genetic variants are also implicated in the pathogenesis of several cancers, the repurposing of targeted therapies developed in oncology has been increasingly investigated for treating vascular malformations. This review provides an update on the current evidence for targeted therapies in slow-flow vascular malformations, particularly in the context of gain-of-function variants in the PI3K/AKT/mTOR pathway.

Indexed as

Molecular Targeted TherapyVascular MalformationsHumansProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesMTOR protein, humanProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinasescapillary malformationslymphatic abnormalitiesprecision medicinevascular malformationsvenous malformations

Identifiers

PMID40095204
PMCPMC12062736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.